These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 36516498)

  • 1. Establishing a signature based on immunogenic cell death-related gene pairs to predict immunotherapy and survival outcomes of patients with hepatocellular carcinoma.
    Ma J; Kuang L; Zhao R
    Aging (Albany NY); 2022 Dec; 14(23):9699-9714. PubMed ID: 36516498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel immunogenic cell death-related genes signature for predicting prognosis, immune landscape and immunotherapy effect in hepatocellular carcinoma.
    Xu G; Jiang Y; Li Y; Ge J; Xu X; Chen D; Wu J
    J Cancer Res Clin Oncol; 2023 Dec; 149(18):16261-16277. PubMed ID: 37698679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel prognostic signature based on immunogenic cell death score predicts outcomes and response to transcatheter arterial chemoembolization and immunotherapy in hepatocellular carcinoma.
    Zhang Y; Yang J; Xie S; Chen H; Zhong J; Lin X; Yu Z; Xia J
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):11411-11429. PubMed ID: 37382674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel prognostic model based on immunogenic cell death-related genes for improved risk stratification in hepatocellular carcinoma patients.
    Liu T; Chen X; Peng B; Liang C; Zhang H; Wang S
    J Cancer Res Clin Oncol; 2023 Sep; 149(12):10255-10267. PubMed ID: 37269346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Construction and validation of a novel signature based on epithelial-mesenchymal transition-related genes to predict prognosis and immunotherapy response in hepatocellular carcinoma by comprehensive analysis of the tumor microenvironment.
    Gao B; Wang Y; Lu S
    Funct Integr Genomics; 2022 Dec; 23(1):6. PubMed ID: 36536232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analyzing molecular typing and clinical application of immunogenic cell death-related genes in hepatocellular carcinoma.
    Lin CF; Chen ZW; Kang FP; Hu JF; Huang L; Liao CY; Lai JL; Huang Y; Wang ZW; Tian YF; Chen S
    BMC Cancer; 2023 Jun; 23(1):522. PubMed ID: 37291495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value and immune landscapes of immunogenic cell death-related lncRNAs in hepatocellular carcinoma.
    Chen W; Shu K; Cai C; Ding J; Zhang X; Zhang W; Wang K
    Biosci Rep; 2023 Sep; 43(9):. PubMed ID: 37584192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular subtypes and a prognostic model for hepatocellular carcinoma based on immune- and immunogenic cell death-related lncRNAs.
    He M; Gu W; Gao Y; Liu Y; Liu J; Li Z
    Front Immunol; 2022; 13():1043827. PubMed ID: 36479122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen-related genes influence immune cell infiltration and immunotherapy response in Hepatocellular Carcinoma.
    Gao B; Wang Y; Li C; Lu S
    Front Immunol; 2023; 14():1114717. PubMed ID: 36814910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of cancer-associated fibroblasts signature for predicting the prognosis and immunotherapy response in hepatocellular carcinoma.
    Ye J; Tian W; Zheng B; Zeng T
    Medicine (Baltimore); 2023 Nov; 102(45):e35938. PubMed ID: 37960718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A T-cell-related signature for prognostic stratification and immunotherapy response in hepatocellular carcinoma based on transcriptomics and single-cell sequencing.
    Chen X; Peng C; Chen Y; Ding B; Liu S; Song Y; Li Y; Sun B; Yang R
    BMC Bioinformatics; 2023 May; 24(1):216. PubMed ID: 37231356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and characterization of a 25-lncRNA prognostic signature for early recurrence in hepatocellular carcinoma.
    Fu Y; Wei X; Han Q; Le J; Ma Y; Lin X; Xu Y; Liu N; Wang X; Kong X; Gu J; Tong Y; Wu H
    BMC Cancer; 2021 Oct; 21(1):1165. PubMed ID: 34717566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a Predictive Immune-Related Gene Signature Associated With Hepatocellular Carcinoma Patient Prognosis.
    Lei J; Zhang D; Yao C; Ding S; Lu Z
    Cancer Control; 2020; 27(1):1073274820977114. PubMed ID: 33269615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel immunogenic cell death-related subtype classification and risk signature for predicting prognosis and immunotherapy efficacy in gastric cancer.
    Dong B; Wu Y; Zhang J; Gu Y; Xie R; He X; Pang X; Wang X; Cui Y
    Front Immunol; 2023; 14():1162876. PubMed ID: 37215130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma.
    Li L; Xie R; Lu G
    Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34027555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N6-methyladenosine (m6A) RNA methylation regulator SNRPC is a prognostic biomarker and is correlated with immunotherapy in hepatocellular carcinoma.
    Cai J; Zhou M; Xu J
    World J Surg Oncol; 2021 Aug; 19(1):241. PubMed ID: 34389000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implications of m6A-associated snRNAs in the prognosis and immunotherapeutic responses of hepatocellular carcinoma.
    Zhang C; Zhang W; Shui Y; Li P; Tian Z; Duan S; Wei Q
    Front Immunol; 2022; 13():1001506. PubMed ID: 36405741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pyrimidine metabolism-related signature for prognostic and immunotherapeutic response prediction in hepatocellular carcinoma by integrating analyses.
    Zhang S; Qin O; Wu S; Xu H; Huang W; Hailiang S
    Aging (Albany NY); 2024 Mar; 16(6):5545-5566. PubMed ID: 38517376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.
    Luo Y; Liu H; Fu H; Ding GS; Teng F
    Front Immunol; 2022; 13():974377. PubMed ID: 36458010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive Molecular Analyses of a Macrophage-Related Gene Signature With Regard to Prognosis, Immune Features, and Biomarkers for Immunotherapy in Hepatocellular Carcinoma Based on WGCNA and the LASSO Algorithm.
    Wang T; Dai L; Shen S; Yang Y; Yang M; Yang X; Qiu Y; Wang W
    Front Immunol; 2022; 13():843408. PubMed ID: 35693827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.